InVivo Therapeutics Holdings Co (NVIVQ)

NVIVQ Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selling, General & Admin	5.78	5.42	5.52	5.16	5.9	7.84
Research & Development	4.08	5.23	4.38	3.94	5.6	4.93
Operating Expenses	9.86	10.65	9.9	9.1	11.5	12.77
Operating Income	-9.86	-10.65	-9.9	-9.1	-11.5	-12.77
Interest Expense / Income	0.15	0.15	0	0	0.25	0.21
Other Expense / Income	-0.68	-0.31	-0.01	-0.02	0.08	10.45
Pretax Income	-9.33	-10.49	-9.9	-9.07	-11.83	-23.42
Net Income	-9.33	-10.49	-9.9	-9.07	-11.83	-23.42
Shares Outstanding (Basic)	3	2	1	0	0	0
Shares Outstanding (Diluted)	3	2	1	0	0	0
Shares Change	123.21%	16.08%	379.40%	1958.36%	101.59%	278.71%
EPS (Basic)	-3.29	-6.83	-7.48	-32.75	-882.00	-3520.25
EPS (Diluted)	-3.29	-6.83	-7.48	-32.75	-882.00	-3520.25
Free Cash Flow	-10.08	-10.64	-8.93	-9.58	-10.33	-12.38
Free Cash Flow Per Share	-3.25	-6.93	-6.75	-34.68	-769.79	-1860.11
EBITDA	-8.76	-9.89	-9.52	-8.75	-11.25	-23.13
Depreciation & Amortization	0.42	0.45	0.37	0.33	0.32	0.09
EBIT	-9.18	-10.34	-9.89	-9.07	-11.58	-23.22

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).